Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials

Linda G Mellbin; Deepak L Bhatt; Jens-Peter David; Kathrine Ekström; Mark C Petrie; Søren Rasmussen; Tina Vilsbøll

doi:10.1093/eurheartj/ehae028

Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials

Eur Heart J. 2024 Apr 14;45(15):1371-1374. doi: 10.1093/eurheartj/ehae028.

Authors

Linda G Mellbin^{1

2}, Deepak L Bhatt³, Jens-Peter David⁴, Kathrine Ekström⁴, Mark C Petrie⁵, Søren Rasmussen⁴, Tina Vilsbøll⁶

Affiliations

¹ Department of Medicine Solna, Karolinska Institutet, Eugeniavägen 27, 171 64 Solna, Stockholm, Sweden.
² Heart Vascular and Neuro Theme, Karolinska University Hospital, K2 Medicin, K2 Kardio Pernow J, 171 77 Solna, Stockholm, Sweden.
³ Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁴ Novo Nordisk A/S, Søborg, Denmark.
⁵ School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
⁶ Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Copenhagen, Denmark.

No abstract available

Keywords: Post hoc analysis; Cardiovascular outcomes trial; Glucagon-like peptide-1 receptor agonist; HbA1c; Major adverse cardiovascular events; PIONEER 6; SUSTAIN 6; Semaglutide; Type 2 diabetes.

MeSH terms

Cardiovascular System*
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptides / therapeutic use
Glycated Hemoglobin
Humans
Hypoglycemic Agents / therapeutic use

Substances

semaglutide
Glycated Hemoglobin
Glucagon-Like Peptides
Hypoglycemic Agents

MeSH terms

Substances

Grants and funding